Author： Kyte Jon Amund
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.5, 2009-05, pp. : 687-694
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
GV 1001 shows potential in patients with non-resectable, untreated pancreatic cancer
Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. :
Access to resources
Recommend
CTL precursor-oriented peptide vaccination in colorectal cancer
Inpharma, Vol. 1, Iss. 1440, 2004-01 ,pp. :
Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients
By Kawano Kouichiro Tsuda Naotake Matsueda Satoko Sasada Tetsuro Watanabe Noriko Ushijima Kimio Yamaguchi Tomohiko Yokomine Masato Itoh Kyogo Yamada Akira Kamura Toshiharu
Immunopharmacology and Immunotoxicology, Vol. 36, Iss. 3, 2014-06 ,pp. :
Telomerase: a potential therapeutic target for cancer
Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. :
Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design, Vol. 8, Iss. 27, 2002-12 ,pp. :